Neuromyelitis optica (NMOSD): who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• AQP4 12
• CD20 4
• CD19 6
• BCMA 8
• IL-6 0
• STAT3 0
• STING 0
• TIM-3 0
• APOE 0
• BTK 0
• FOXP3 0
• IGF1R 0
• IL-1 0
• PD-1 0
• PD-L1 0
• PI3K 0
• PPAR 0
• TIGIT 0
• YAP 0

4 of 4+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · U54

  PRIME-CORD: Precision Research in Inflammatory & Ischemic Myelopathies-CORD Consortium

  Johns Hopkins University· Baltimore, United States· US$1,379,043 awarded in fiscal year 2026· until Jul 2031

• NIH NIAID · R21

  CSF Proteome of Post Treatment Lyme Disease

  Bioscience Development, Inc.· New York, United States· US$210,000 awarded in fiscal year 2026· until Aug 2028

• NIH NEI · F32

  Ultrastructural development and regeneration of nodes of Ranvier

  University of California Berkeley· Berkeley, United States· US$76,780 awarded in fiscal year 2026· until Aug 2029

• NIH FIC · RF1

  Capacity Building for the Diagnosis and Treatment of Neuromyelitis Optica using Point of Care Aquaporin-4 Antibody Testing

  Northwestern University· Chicago, United States· US$111,432 awarded in fiscal year 2026· until Aug 2027

• NIH NIAID · R01

  Unveiling the Molecular Mechanism Underlying Anti-Aquaporin-4 Responses in Neuromyelitis Optica Spectrum Disorders

  Northwestern University· Chicago, United States· US$480,000 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  B cell-orchestrated tolerization of T cell-dependent B cell-mediated autoimmune diseases (Breaking Bad)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €2,373,592· until Jan 2031

  The disease is named only in the funder's project summary, not in the title.

6 of 19 running projects, newest first. Listed amounts together: US$11.9m + €2.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Mendelian Randomization Analysis 5
• Gene Expression Profiling 2
• Proteomics 3
• Metabolomics 2
• Flow Cytometry 2
• Positron-Emission Tomography 2
• Magnetic Resonance Imaging 84
• Machine Learning 3
• Deep Learning 1
• Cohort Studies 23
• Genome-Wide Association Study 2

• Proportion and Clinical Characteristics of Double-Seronegative NMOSD in a Multicenter Real-World Cohort.

  Eur J Neurol, Nov 2026

• Long-term neuropsychiatric outcomes in offspring of mothers with multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study.

  Mult Scler Relat Disord, Oct 2026

• Efficacy and Safety of Multidisciplinary Sandwich Regimen in AQP4-IgG+ NMOSD With Preconception B-Cell Depletion During Perigravidity.

  CNS Neurosci Ther, Oct 2026

• Optimal strategies for treatment discontinuation in MOG antibody-associated disease.

  Brain, Sept 2026

• Clinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Multicenter Cohort Study.

  Neurol Neuroimmunol Neuroinflamm, Aug 2026

• Comprehensive factors influencing cerebrospinal fluid leukocytosis in myelin oligodendrocyte glycoprotein antibody-associated disease.

  BMC Neurol, Aug 2026

• Clinical and serological features of systemic autoimmune overlap in AQP4-IgG positive neuromyelitis optica spectrum disorder: a Mexican cohort study.

  Mult Scler Relat Disord, Aug 2026

• Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

  Neurology, Jul 2026

• Prognostic Biomarker Signature of Relapse in Neuromyelitis Optica Spectrum Disorders in the CIRCLES Observational Study.

  Neurol Neuroimmunol Neuroinflamm, Jun 2026

• French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

  Neurology, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.